When it comes to the war on cancer and its side effects, Access Pharmaceuticals is taking a proactive stance. This Dallas, Texas based biopharmaceutical company develops and brings to market proprietary products for the treatment and supportive care of those with cancer. They trade through the OTCBB and have a market capitalization of $5.1M.
Access, as an emerging drug manufacturer, has a product called ProLindac(TM) which is in Phase II clinical testing. This drug is in development for patients with ovarian cancer. With this product, Access seeks ways to deliver a powerful and cytotoxic platinum drug to tumors, while protecting normal tissue.
They are also developing Cobalamin(TM) – mediated targeted delivery and oral drug delivery. The concept behind this research is to formulate ways to deliver drugs orally by having particles coated with Cobalamin. This research is promising for the delivery of proteins and peptides. Access is researching insulin delivery orally as well with this process. The physical and chemical properties of some drugs prohibit oral ingestion of them, but Access continues to research the use of Cobalamin to overcome this obstacle.
The Food and Drug Administration gave marketing allowance to Access Pharmaceuticals for their MuGard(TM) product. This oral rinse is to combat the side effects of some cancer therapies, which results in ulceration of the oral cavity. For the prevention of this mucositis, MuGard provides a protective coating to the mucosal surfaces inside a patient’s mouth.
Access is also developing another product in association with Virium Pharmaceuticals. It’s an agent called Phenylbutyrate (PB). This product shows promise in fighting cancer because research shows it may act as an HDAC inhibitor. HDAC inhibitors suppress certain enzymes found in cancer cells.
Access Pharmaceuticals continues to explore new avenues in drug therapy and patient care. Their clinical and regulatory team works together to develop and commercialize products and get them to those who need them. It is a demanding, costly, time-consuming, heavily regulated process; however, Access Pharmaceuticals knows the results of this process can bring hope to many.
Let us hear your thoughts below:
